Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer’s disease in individuals with subjective cognitive decline

[1] Bateman RJ(2019)Plasma biomarkers of AD emerging as essential tools for drug development: an EU/US CTAD task force report J Prev Alzheimers Dis 6 169-173

[2] Blennow K(2015)Clinical use of amyloid-positron emission tomography neuroimaging: Practical and bioethical considerations Alzheimers Dement Diagn Assess Dis Monit 1 358-367

[3] Doody R(2013)Predicting Alzheimer disease with β-amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing Ann Neurol 74 905-913

[4] Hendrix S(2015)Amyloid biomarkers in Alzheimer’s disease Trends Pharmacol Sci 36 297-309

[5] Lovestone S(2004)Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B Ann Neurol 55 306-319

[6] Salloway S(2010)Cerebrospinal fluid and plasma biomarkers in Alzheimer disease Nat Rev Neurol 6 131-144

[7] Witte MM(2017)Concordance between different amyloid immunoassays and visual amyloid positron emission tomographic assessment JAMA Neurol 74 1492-1501

[8] Foster NL(2016)Reference measurement procedure for CSF amyloid beta (Aβ)1–42 and the CSF Aβ1–42/Aβ1–40 ratio – a cross-validation study against amyloid PET J Neurochem 139 651-658

[9] Fleisher AS(2016)CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease Ann Clin Transl Neurol 3 154-165

[10] Williams MM(2007)Prediction of Alzheimer’s disease using the CSF Aβ42/Aβ40 ratio in patients with mild cognitive impairment Dement Geriatr Cogn Disord 23 316-320

[1] Bateman RJ(2019)Plasma biomarkers of AD emerging as essential tools for drug development: an EU/US CTAD task force report J Prev Alzheimers Dis 6 169-173

[2] Blennow K(2015)Clinical use of amyloid-positron emission tomography neuroimaging: Practical and bioethical considerations Alzheimers Dement Diagn Assess Dis Monit 1 358-367

[3] Doody R(2013)Predicting Alzheimer disease with β-amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing Ann Neurol 74 905-913

[4] Hendrix S(2015)Amyloid biomarkers in Alzheimer’s disease Trends Pharmacol Sci 36 297-309

[5] Lovestone S(2004)Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B Ann Neurol 55 306-319

[6] Salloway S(2010)Cerebrospinal fluid and plasma biomarkers in Alzheimer disease Nat Rev Neurol 6 131-144

[7] Witte MM(2017)Concordance between different amyloid immunoassays and visual amyloid positron emission tomographic assessment JAMA Neurol 74 1492-1501

[8] Foster NL(2016)Reference measurement procedure for CSF amyloid beta (Aβ)1–42 and the CSF Aβ1–42/Aβ1–40 ratio – a cross-validation study against amyloid PET J Neurochem 139 651-658

[9] Fleisher AS(2016)CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease Ann Clin Transl Neurol 3 154-165

[10] Williams MM(2007)Prediction of Alzheimer’s disease using the CSF Aβ42/Aβ40 ratio in patients with mild cognitive impairment Dement Geriatr Cogn Disord 23 316-320